Unregistered Sales of Equity Securities

Business Context and Reporting Period

This Form 8-K reports an unregistered sale of equity securities by Coeptis Therapeutics Holdings, Inc. (the filing’s registrant; request metadata identifies “Z Squared Inc.”). The reported event occurred on September 29, 2023, and the filing was signed on October 12, 2023.

Transaction and Key Financial Terms

  • Biofin Ventures, LLC: The company agreed to issue 2,400,000 common shares for total consideration of $2.4 million, consisting of $400,000 in cash and $2.0 million under a promissory note.
  • AG Bio Life Capital I LP: The company agreed to issue 600,000 common shares for total consideration of $600,000, consisting of $100,000 in cash and $500,000 under a promissory note.
  • Total securities issued: 3,000,000 common shares for aggregate consideration of $3.0 million, including $500,000 in cash and $2.5 million of notes receivable.
  • Both notes mature no later than August 30, 2024.
  • Interest begins as of the company’s next registration statement at 6% annually, calculated using actual days elapsed over a 365-day year. The rate increases to 18% upon an event of default.
  • Each investor may prepay its note, in whole or in part, with at least 30 days’ prior written notice.

Material Changes, Outlook, Risks, and Unusual Items

  • The transaction increases the company’s common shares outstanding by 3.0 million shares, subject to the filing’s terms and any other applicable issuance conditions.
  • The company receives only $500,000 in immediate cash; the remaining $2.5 million is represented by investor promissory notes due in 2024.
  • Biofin and AG have obligations to contribute proceeds from any sale of their shares to the company if those shares are sold before the applicable maturity date.
  • The filing does not provide revenue, profit, operating cash flow, liquidity balances, debt balances, margins, or management guidance.
  • Collection of the notes is subject to repayment by the investors; default would increase the stated interest rate to 18% but may also create credit and liquidity risk for the company.

Investor Verification Items

  • Verify the identity of the registrant, because the filing names Coeptis Therapeutics Holdings, Inc., while the request metadata names Z Squared Inc.
  • Confirm the final share issuance, registration status, applicable exemption from registration, and resulting dilution.
  • Review the executed Biofin Note and AG Note, including default provisions, collateral or security, and enforceability.
  • Confirm whether the $500,000 cash consideration was received and whether the notes were recorded as receivables.
  • Monitor repayment of the $2.5 million in notes by August 30, 2024 and any sales of the issued shares before maturity.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.